复方苦参注射液联合TAC方案新辅助化疗对局部晚期乳腺癌患者疗效及预后的影响  

Effects of Compound Kushen Injection Combined with TAC Neoadjuvant Chemotherapy on Curative Effect and Prognosis of Patients with Locally Advanced Breast Cancer

作　　者：姚得顺 王志武[2] 胡万宁[3] 刘春玲 马金秋[5] 蔡海峰[1] YAO Deshun;WANG Zhiwu;HU Wanning;LIU Chunling;MA Jinqiu;CAI Haifeng(Breast Surgery Department Two ,Tangshan People's Hospital ,Tangshan 063000, Hebei, China;Chemotherapy and RadiationTherapy Department,Tangshan People's Hospital,Tangshan 063000, Hebei, China;Oncology Surgery,Tangshan People's Hospital,Tangshan 063000, Hebei, China;Pathological Department,Tangshan People's Hospital,Tangshan 063000, Hebei, China;Ultrasonic Department,Tangshan People's Hospital,Tangshan 063000, Hebei,China)

机构地区：[1]唐山市人民医院乳腺外二科,河北唐山063000 [2]唐山市人民医院放化科,河北唐山063000 [3]唐山市人民医院肿瘤外科,河北唐山063000 [4]唐山市人民医院病理科,河北唐山063000 [5]唐山市人民医院超声科,河北唐山063000

出　　处：《辽宁中医杂志》2019年第3期556-559,共4页Liaoning Journal of Traditional Chinese Medicine

摘　　要：目的:探讨复方苦参注射液联合TAC方案新辅助化疗治疗局部晚期乳腺癌的疗效,以及对患者预后的影响。方法:纳入75例采用TAC方案新辅助化疗(对照组)和75例采用复方苦参注射液联合TAC方案新辅助化疗(研究组)的晚期乳腺癌患者进行研究,RECIST1.1实体肿瘤化疗疗效评价标准和美国国立癌症研究所化疗毒性反应及分度标准(NCI-CTCAEV4.0)评价疗效和安全性,Kaplan-Meier分析患者3年生存率、外周血淋巴细胞免疫表型(CD_3^+、CD_4^+、CD_8^+及CD_4^+/CD_8^+)进行比较分析。结果:研究组患者CR23例,PR15例,SD30例,PD7例,DCR 90.67%,高于对照组(P<0.05),RR 50.67%,与对照组无差异(P>0.05),研究组不良反应率为5.33%,对照组14.67%,两组对比差异具有统计学意义(χ~2=13.925,P<0.05)。两组患者随访3-5年,中位随访2.8年,研究组1年生存率与对照组对比差异无统计学意义(83.25%VS 81.05%,P>0.05),2年生存率对比(75.92%VS 63.42%),3年生存率对比(67.38%VS 53.49%),差异具有统计学意义(P<0.05)。观察组CD_3^+、CD_4^+及CD_4^+/CD_8^+水平均高于对照组,差异具有统计学意义(F=4.14、6.20、5.21,P<0.05);观察组CD_8^+水平低于对照组,差异具有统计学意义(F=6.78,P=0.01)。结论:复方苦参注射液联合TAC方案新辅助化疗可提高局部晚期乳腺癌治疗疗效和生存率,降低不良反应。Objective: To investigate the effect of Compound Kushen Injection combined with TAC regimen neoadjuvant chemotherapy in the treatment of locally advanced breast cancer and its effect on prognosis. Methods: Seventy-five patients with advanced breast cancer who underwent neoadjuvant chemotherapy with TAC regimen( control group) and 75 patients with neoadjuvant chemotherapy with TAC regimen( group) were studied. RECIST1. 1 solid tumor chemotherapy efficacy evaluation. The standard and the National Cancer Institute’s Chemotherapy Response and Grading Criteria( NCI-CTCAEV4. 0) were used to evaluate efficacy and safety,and Kaplan-Meier analysis of patients’ 3-year survival rate. Peripheral blood lymphocyte immunophenotype( CD3^+,CD4^+,CD8^+and CD4^+/CD8^+) were comparatively analyzed. Results: There were 23 cases of CR in the study group,15 cases of PR,30 cases of SD,7 cases of PD,DCR 90. 67%,higher than the control group( P < 0. 05),RR 50. 67%,and no difference with the control group( P > 0. 05). The adverse reaction rate was 5. 33% and the control group was 14. 67%. There was a statistically significant difference between the two groups(χ^2= 13. 925,P < 0. 05). The two groups of patients were followed up for 3-5 years. The median follow-up period was 2. 8 years. There was no significant difference between the 1-year survival rate of the study group and the control group( 83. 25% VS 81. 05%,P > 0. 05),and the 2-year survival rate comparison( 75. 92%VS 63. 42%),3-year survival rate comparison( 67. 38% VS 53. 49%),the difference was statistically significant( P < 0. 05).The levels of CD3^+,CD4^+and CD4^+/CD8^+in the observation group were higher than those in the control group( F = 4. 14,6. 20,5. 21,P < 0. 05),and the levels of CD8^+in the observation group were lower than those in the control group( F = 6. 78,P =0. 01). Conclusion: Compound Kushen Injection combined with TAC regimen for neoadjuvant chemotherapy can improve the therapeutic efficacy and survival rate of locally advanced breast cancer and reduce adve

关 键 词：复方苦参注射 TAC方案 局部晚期乳腺癌 预后 

分 类 号：R737.9[医药卫生—肿瘤]